Table 2 Pharmacokinetic parameters of total d- and l-nebivolol plasma levels obtained from arterial blood samples in control and L-NAME rats after i.v. administration of drug (3 and 10 mg kg−1): AUC, α, β, Cl, Vdss, Cmax and AIC

From: Enantioselective pharmacokinetics and cardiovascular effects of nebivolol in L-NAME hypertensive rats

Enantiomer

D-nebivolol

L-nebivolol

Experimental group

Control rats (n=12)

L -NAME rats (n=12)

Control rats (n=12)

L -NAME rats (n=12)

Dose

3 mg kg−1

10 mg kg−1

3 mg kg−1

10 mg kg−1

3 mg kg−1

10 mg kg−1

3 mg kg−1

10 mg kg−1

α (h−1)

8.1±2.7

11.6±0.1

12.8±0.8

8.9±1.8

14.9±0.1

12.0±1.7

11.4±1.8

10.8±1.7

β (h−1)

0.36±0.11

0.35±0.07

0.35±0.04

0.33±0.08

0.43±0.06

0.66±0.08a

0.49±0.11

0.47±0.14

Vdss (l)

3.8±0.3

5.4±1.8

4.2±1.0

5.5±1.0

8.3±0.8

13.9±2.0a

9.7.±2.1

12.7±2.3a

Cl (ml min−1)

23.4±6.2

32.2±3.5

22.3±5.7

28.3±2.6

62.9±5.6a

82±11.8a

71.8±18.1a

74.4±15.2a

Cmax (ng ml−1)

1522±534

2620±154b

1350±238

2792±306b

418±41

1239±391a,b

594±280

1356±258a,b

AUC0−∞ (ng ml h−1)

808±70

2120±365b

1044±257

2593±364b

596±134

1244±270a,b

552±162

1409±197a,b

r 2

0.993 (0.988–0.999)

0.991 (0.981–0.998)

0.998 (0.996–0.999)

0.994 (0.984–0.999)

0.998 (0.998–0.999)

0.996 (0.994–0.997)

0.997 (0.995–0.999)

0.992 (0.967–0.999)

AIC

59.9 (46.6–84.7)

81.8 (63.1–103.5)

53.8 (28.9–71.3)

89.9 (76.8–109)

46.8 (33.2–66.0)

64.7 (51.0–76.8)

44.8 (32.6–54.5)

68.5 (31.6–98.2)

  1. Abbreviations: α, constant of distribution; AIC, Akaike Information Criterion; ANOVA, analysis of variance; AUC, area under the curve; β, constant of elimination; Cl, clearance; Cmax, extrapolated maximal concentration; Vdss, steady-state volume of distribution.
  2. Data are expressed as mean±s.e.m. Goodness of fit indicators are expressed as mean (range).
  3. aP<0.05 vs. d-nebivolol by two-way ANOVA followed by Bonferroni post-test.
  4. bP<0.05 vs. 3 mg kg−1 by two-way ANOVA followed by Bonferroni post-test.
Back to article page